Drug intelligence / Profile preview

NK939

Development stage: Unknown
Lead developer: Nippon Kayaku
Modality: Small Molecules
Administration: Intra-arterial

Overview

NK939 is an investigational hemostatic embolic agent developed by Nippon Kayaku Co., Ltd. for the treatment of hypervascular tumors and arteriovenous malformations (AVMs). Administered via intra-arterial injection, NK939 functions by physically occluding the blood vessels that supply the target lesion. This mechanical blockage induces localized ischemia and subsequent necrosis in tumors or stabilizes blood flow in vascular malformations. It is currently being evaluated in Phase 2 clinical trials in Japan as a localized interventional therapy for these conditions.

Beyond the preview

Go deeper on NK939.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NK939.

Explore the full profile